Toyama-shi, Japan
Toyama-shi, Japan

Time filter

Source Type

Patent
Toyama Chemical Co. | Date: 2015-02-16

Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.


Patent
Taisho Pharmaceutical Co. and Toyama Chemical Co. | Date: 2015-04-21

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:


Patent
Toyama Chemical Co. and Fujifilm Co. | Date: 2015-09-09

A novel amine derivative expressed by general formula (1)^(1), G^(2), and G^(3) are the same or different and represent CH or a nitrogen atom; R^(1) represents a chlorine atom, an optionally-substituted C_(3-8) cycloalkyl group, or the like; R^(2) represents -COOR^(5) (in the formula, R^(5) represents a hydrogen atom or a carboxyl protective group), or the like; R^(3) represents a hydrogen atom, or the like; and R^(4) represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.


A method for treating the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse, by administering a benzopyran derivative of the following formula or a salt thereof, where R^(1 )represents an optionally substituted C_(1-6 )alkyl group, one of R^(2 )and R^(3 )represents a hydrogen atom, and the other of R^(2 )and R^(3 )represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group.


A method for inhibiting macrophage migration and a method for treating neuropathic pain, by administering a benzopyran derivative of the following formula, or a salt thereof, where R represents an optionally substituted C_(1-6 )alkyl group, one of R^(2 )and R^(3 )represents a hydrogen atom, and the other of R^(2 )and R^(3 )represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group.


Patent
Toyama Chemical Co. | Date: 2016-01-20

A compound represented by general formula (1) (wherein R^(1) represents a hydrogen atom, an optionally substituted C_(1-6) alkyl group or the like; R^(2) represents a hydrogen atom, an optionally substituted C_(1-6) alkyl group or the like; R^(3) represents a hydrogen atom or an optionally substituted C_(1-6) alkyl group; R^(4) represents a hydrogen atom, an optionally substituted C_(1-6) alkyl group or the like; X^(1) represents an optionally substituted C_(2-6) alkynylene group or the like; A represents an optionally substituted bivalent aromatic hydrocarbon group or the like; X^(2) represents an optionally substituted C_(1-6) alkylene group or the like; Y^(1) represents an oxygen atom or the like; and R^(5) represents a hydrogen atom or the like) or a salt thereof is useful as an antibacterial agent.


Patent
Toyama Chemical Co. | Date: 2016-12-21

Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.


A benzopyran derivative represented by general formula [1], or a salt thereof, is useful in therapeutic or preventive treatment of disease, wherein said therapeutic or preventive treatment is effective because said benzopyran derivative, or salt thereof, binds to MIF, has an MIF inhibitory effect, and inhibits MIF. [In the formula, R^(1) represents an optionally substituted C_(1-6) alkyl group, one of R^(2) and R^(3) represents a hydrogen atom, and the other of R^(2) and R^(3) represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group, or an optionally substituted aryl group.]


Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1]^(1) and R^(2) are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C_(1-6) alkyl group, an optionally substituted aryl group, etc.; R^(3) represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.


A benzopyran derivative represented by general formula [1], or a salt thereof, is useful in therapeutic or preventive treatment of disease, wherein said therapeutic or preventive treatment is effective because said benzopyran derivative, or salt thereof, binds to MIF, has an MIF inhibitory effect, and inhibits MIF. [In the formula, R^(1) represents an optionally substituted C_(1-6) alkyl group, one of R^(2) and R^(3) represents a hydrogen atom, and the other of R^(2) and R^(3) represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group, or an optionally substituted aryl group.]

Loading Toyama Chemical Co. collaborators
Loading Toyama Chemical Co. collaborators